

#24

Practitioner's Docket No. MWH-0031US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liggett, Stephen B.

Application No.: To be determined

Group No.: To be determined

Filed: 09/12/2001

Examiner: To be determined

For: Variation in Drug Response Related to Polymorphisms in Beta 2-Adrenergic Receptor

Box Sequence

Assistant Commissioner for Patents

Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE

CERTIFICATION UNDER 37 C.F.R. sections 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*;

Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING



deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. section 1.8(a)

☐ with sufficient postage as first class mail.

37 C.F.R. section 1.10*



as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

E2594656508 US

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Date: Sept 12, 2001

Melodie W. Henderson
Signature

Melodie W. Henderson
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

IDENTIFICATION OF PERSON MAKING STATEMENT

1. I, Gisela M. Field, state the following:

ITEMS BEING SUBMITTED

2. Submitted herewith is/are:

Please transfer to this application, in accordance with 37 C.F.R. section 1.821(e), the computer readable copy from applicant's other application identified as follows:

In re application of: Ligget, Stephen B.

Application No.: PCT/US00/06502

Group No.: 1656

Filed: 03/10/2000

Examiner: Scott Houtteman

For: Variation in Drug Response Related to Polymorphisms in Beta2-Adrenergic Receptor

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form
(other application)

"Sequence Identifier"
(this application)

PCT/US00/06502

SEQ ID NOS:1-2

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

3. I hereby state:

That the content of the "Sequence Listing" and computer readable copy originally submitted are the same, as required in 37 C.F.R. section 1.821(g).

All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

09/936499

518 Rec'd PCT/PTO 12 SEP 2001

STATUS

4. Applicant is other than a small entity.
5. It is believed that no fee is required, but if that is incorrect, you are hereby authorized to debit deposit account 50-1293 for any deficiency.

SIGNATURE(s)

9/12/01

Date

Reg. No. 47,562
Tel. No. (203) 786-3473

Gisela M. Field
Signature

Gisela M. Field
Genaissance Pharmaceuticals, Inc.
5 Science Park
New Haven, CT 06511
USA